What Doctors Evaluate Before Prescribing Tirzepatide
Before tirzepatide is prescribed, doctors do not usually rely on weight alone. Suitability is typically assessed through a broader clinical review that includes the person’s diagnosis, weight-related complications, current medicines, relevant medical history, contraindications, and whether the patient can safely participate in follow-up. This matters because tirzepatide is a prescription medicine with important precautions, and in Singapore, HSA’s public materials currently list Mounjaro as indicated for improving glycaemic control in adults with type 2 diabetes mellitus, with the latest approved prescribing information to be checked through the HSA register.
Key Takeaways
Doctors usually assess clinical suitability, not just body size, before prescribing tirzepatide. This includes diagnosis, comorbidities, current medicines, and safety risks.
A key screening step is checking for contraindications, including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and prior serious hypersensitivity to tirzepatide.
Doctors also review pancreatitis risk, gallbladder history, kidney risk from dehydration, and severe gastrointestinal symptoms or gastroparesis because these issues affect safety and follow-up.
Pregnancy planning and contraception are part of suitability assessment because tirzepatide is not recommended in pregnancy, and delayed gastric emptying can reduce the effectiveness of oral hormonal contraceptives during initiation and dose escalation.
Doctors also consider whether the person is prepared for diet, activity, dose titration, monitoring, and ongoing review, because tirzepatide is not intended as a stand-alone shortcut.
Why doctors assess more than body weight alone
A prescribing decision is usually based on overall clinical context rather than a single number on the scale. Current obesity-management guidance emphasizes an initial assessment that checks eligibility, takes a full medical history, reviews concomitant medicines, and identifies weight-related comorbidities. More broadly, obesity-care frameworks recommend assessing both body size and the presence or severity of weight-related complications, because risk and treatment choice are not determined by BMI alone.
In practice, that means doctors often ask not only about weight trajectory, but also about diabetes, blood pressure, sleep apnoea, dyslipidaemia, mobility limitations, reflux symptoms, liver issues, and previous attempts at lifestyle treatment. The clinical question is whether tirzepatide fits the patient’s health profile and treatment goals, not simply whether a patient wants to lose weight. This is an inference drawn from obesity assessment guidance and tirzepatide prescribing frameworks.
Diagnosis, weight-related complications, and treatment goals
One of the first things doctors evaluate is the reason tirzepatide is being considered. In Singapore, public HSA materials currently describe Mounjaro as indicated for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control. HSA also advises checking the latest approved prescribing information through the online register.
Beyond diagnosis, clinicians typically assess whether there are obesity-related or metabolic complications that increase the importance of treatment. Modern obesity guidance recommends identifying comorbidities after the initial assessment, because treatment decisions become more clinically meaningful when they are linked to health impact rather than appearance alone.
Doctors may also discuss what the patient is hoping to achieve. Some patients are mainly focused on glycaemic control, while others are concerned about appetite regulation, cardiovascular risk factors, or longer-term weight trajectory. Clarifying the treatment goal helps determine whether tirzepatide is appropriate and what kind of monitoring will matter most. This is an inference based on prescribing guidance that emphasizes the person’s clinical profile and treatment goals.
Medical history and contraindications
A major part of pre-prescribing review is ruling out situations in which tirzepatide should not be used or should be used only with caution.
Thyroid-related contraindications
The prescribing information states that Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2.
That is why doctors often ask about family history of rare endocrine cancers rather than focusing only on common thyroid problems. A routine history of hypothyroidism, for example, is not the same as a history suggesting MTC or MEN2, and careful clarification matters.
Previous serious drug allergy
Doctors also check for prior serious hypersensitivity reactions. The prescribing information says tirzepatide should not be used in patients with a previous serious hypersensitivity reaction to tirzepatide or its excipients, and it advises caution in people with prior anaphylaxis or angioedema to related agents.
Pancreatitis and gallbladder history
The HSA summary report notes that Mounjaro has not been studied in patients with a history of pancreatitis. The prescribing information also warns that acute pancreatitis has been observed and that treatment should be discontinued if pancreatitis is suspected. Gallbladder disease events such as cholelithiasis and cholecystitis have also been reported.
This does not mean every person with abdominal symptoms is automatically unsuitable. It does mean doctors usually ask carefully about past pancreatitis, recurrent upper abdominal pain, gallstones, or biliary disease before prescribing.
Gastrointestinal tolerance and severe gastroparesis
Because tirzepatide commonly causes gastrointestinal adverse effects and is not recommended in severe gastroparesis, doctors usually ask about nausea, vomiting, severe reflux, delayed gastric emptying, and whether the patient already struggles to tolerate meals normally.
This is especially important because a medicine that reduces appetite may be poorly tolerated in someone who already has significant upper gastrointestinal symptoms at baseline.
Current medicines and interaction-related review
Doctors usually review the full medication list before prescribing tirzepatide. This is partly because tirzepatide can increase hypoglycaemia risk when used together with insulin or sulfonylureas, and the prescribing information notes that dose reduction of those agents may be needed.
Medication review also matters because tirzepatide delays gastric emptying. Some oral medicines with a narrow therapeutic index may need closer monitoring, especially during initiation and dose escalation.
In practice, this means doctors may pay extra attention to diabetes medicines, time-sensitive oral medicines, and any treatment where small shifts in absorption could matter clinically. The goal is not just to start tirzepatide, but to do so without destabilising the rest of the patient’s care.
Kidney risk, hydration, and baseline tolerability
Doctors often evaluate whether a patient is likely to tolerate the early gastrointestinal phase safely. Tirzepatide’s prescribing information warns about acute kidney injury due to volume depletion, especially when nausea, vomiting, or diarrhoea lead to dehydration, and advises monitoring renal function in patients reporting such adverse reactions.
That is why clinicians commonly ask about prior dehydration episodes, chronic kidney disease, poor fluid intake, vomiting-prone illnesses, or frailty. The issue is not only renal disease on paper. It is whether the person is likely to cope safely if the medicine causes appetite suppression together with nausea or loose stools.
Pregnancy, reproductive planning, and contraception
Pregnancy planning is an important part of tirzepatide suitability screening. Tirzepatide is not recommended during pregnancy and advises asking whether the person plans on becoming pregnant.
The prescribing information also states that available data in pregnancy are insufficient and that animal studies suggest potential fetal risk. In addition, because tirzepatide can reduce the efficacy of oral hormonal contraceptives through delayed gastric emptying, patients using oral contraceptives are advised to switch to a non-oral method or add a barrier method for 4 weeks after starting treatment and for 4 weeks after each dose escalation.
For doctors, this means suitability is not just a question of current pregnancy status. It also includes near-term pregnancy intentions and whether contraception advice needs to be built into the treatment plan.
Readiness for long-term follow-up
Suitability also includes behavioural and practical readiness. The initial assessment, clinicians should check that the person is eligible and willing to engage with a reduced-calorie diet and increased physical activity.
That does not mean patients must already have perfect habits before treatment begins. It does mean doctors usually want to know whether the person can attend follow-up, understand dose escalation, respond appropriately to side effects, and participate in a broader care plan. StatPearls similarly describes patient assessment in terms of clinical profile, treatment goals, and regular monitoring of glycaemic control and weight changes.
This is one of the most important parts of suitability, because tirzepatide is generally managed as an ongoing treatment process rather than a single prescription event.
What “doctor evaluation” usually looks like in practice
A real-world prescribing review often includes:
confirmation of diagnosis and treatment purpose
measurement of weight and related metabolic risk
review of comorbidities and previous treatment efforts
screening for thyroid cancer history, MEN2, severe allergy, pancreatitis, gallbladder disease, and severe gastrointestinal problems
review of insulin, sulfonylureas, and other oral medicines
discussion of pregnancy plans, contraception, and follow-up expectations
The article’s core point is that doctors are evaluating the whole safety and care pathway, not just whether a patient asks for the medication.
Takeaway
Before prescribing tirzepatide, doctors usually evaluate far more than body weight. They review diagnosis, metabolic complications, contraindications, current medicines, gastrointestinal and pancreatitis history, dehydration and kidney risk, pregnancy planning, and whether the patient can engage in safe follow-up. In Singapore, that assessment should remain especially careful because Mounjaro is a prescription medicine and HSA’s public listing currently identifies it for glycaemic control in adults with type 2 diabetes mellitus. The clinical aim is not just access to a medicine, but a safe and appropriate treatment fit.
To better understand how suitability is assessed in real clinical settings, including contraindications, treatment goals, and how tirzepatide prescribing is approached in Singapore, you can refer to How Singapore Doctors Determine Suitability for Mounjaro Medication.
FAQ
Do doctors only look at BMI before prescribing tirzepatide?
No. Current assessment frameworks emphasize medical history, concomitant medicines, and weight-related comorbidities, not body size alone.
What conditions can make tirzepatide unsuitable?
Important reasons for concern include a personal or family history of medullary thyroid carcinoma, MEN2, previous serious hypersensitivity to tirzepatide, severe gastroparesis, and careful review in those with pancreatitis or gallbladder history.
Why do doctors ask about pregnancy plans?
Because tirzepatide is not recommended during pregnancy, and treatment planning may need to account for future conception and contraception choices.
Why is my medication list important?
Tirzepatide can increase hypoglycaemia risk with insulin or sulfonylureas, and delayed gastric emptying can affect the handling of some oral medicines during dose escalation.
Is doctor follow-up really necessary?
Yes. Tirzepatide prescribing guidance and clinical references frame treatment as something that requires dose titration, monitoring, and review of response and tolerability over time.